Onasemnogene abeparvovec

News and Video Search Results

News coverage

New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy

GlobeNewswire 06 Mar 2024

· New data from the RESPOND study show that neurofilament levels, an indicator of neurodegeneration, were reduced in nearly all..

Novartis presents new data on safety and efficacy of Zolgensma, including maintained and improved motor milestones in older and heavier children with SMA
GlobeNewswire 04 Mar 2024
Global Market for Treatments for Syndromes of Progressive Ataxia and Weakness Disorders: 2022-23 Data, Forecasts for 2024- 2026 and CAGR Projections through 2028
GlobeNewswire 22 Dec 2023
New Data at Cure SMA Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs After Gene Therapy
GlobeNewswire 30 Jun 2023
Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing; 100% achievement of all assessed milestones in children treated prior to SMA symptom onset
GlobeNewswire 19 Mar 2023

0 shares 1 views

You might like

Onasemnogene abeparvovec media coverage

Positive New Data for Genentech’s Evrysdi in Largest Trial Ever Undertaken in Patients With Previously-Treated Spinal Muscular Atrophy (SMA)

Positive New Data for Genentech’s Evrysdi in Largest Trial Ever Undertaken in Patients With Previously-Treated Spinal Muscular Atrophy (SMA)

Business Wire 12 Oct 2022

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced..

Global Spinal Muscular Atrophy Treatment Market Report 2022: Increasing Reimbursement Access To Patients Bolsters Growth
GlobeNewswire 06 Jan 2023
Spinal Muscular Atrophy Treatment Market Report 2022: Collaborations Between Pharmaceutical Companies and Research Institutes Fosters Progress and Market Growth
GlobeNewswire 23 Dec 2022
The Global Spinal Muscular Atrophy Treatment Market size is expected to reach $11.4 billion by 2028, rising at a market growth of 17.8% CAGR during the forecast period
GlobeNewswire 20 Dec 2022
Gene therapy R&D market is projected to grow at a CAGR of 30.1% by 2032: Visiongain Reports Ltd
GlobeNewswire 29 Nov 2022

Advertisement

More coverage

Positive new data for Roche’s Evrysdi in largest trial ever undertaken in patients with previously-treated spinal muscular atrophy (SMA)

GlobeNewswire 12 Oct 2022

· *New two-year Evrysdi data** show improvement or maintenance of motor function in people with SMA, a progressive neuromuscular..

Roche to present new data from its expanding neuromuscular disease portfolio at World Muscle Society 2022
GlobeNewswire 05 Oct 2022
Novartis expands Zolgensma manufacturing capacity with approval of multi-product North Carolina facility
GlobeNewswire 05 Apr 2022
Novartis data again demonstrate age-appropriate development when Zolgensma is used presymptomatically, and post-hoc data reveal SMA Type 1 patients could speak, swallow and maintain airway protection
GlobeNewswire 13 Mar 2022
Roche to present new Evrysdi data at MDA 2022 and highlight expanding neuromuscular disease portfolio
GlobeNewswire 08 Mar 2022